Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017
Open Access
- 28 October 2020
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 497, 221-228
- https://doi.org/10.1016/j.canlet.2020.10.039
Abstract
No abstract availableKeywords
Funding Information
- Johns Hopkins Pancreatic Cancer Precision Medicine Program
This publication has 31 references indexed in Scilit:
- Whole genomes redefine the mutational landscape of pancreatic cancerNature, 2015
- Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cellsGynecologic Oncology, 2015
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal CarcinomasClinical Cancer Research, 2014
- Discovery and saturation analysis of cancer genes across 21 tumour typesNature, 2014
- ClinVar: public archive of relationships among sequence variation and human phenotypeNucleic Acids Research, 2013
- Recent progress in pancreatic cancerCA: A Cancer Journal for Clinicians, 2013
- BRCAness: Finding the Achilles Heel in Ovarian CancerThe Oncologist, 2012
- Targeted Therapies for Lung CancerThe Cancer Journal, 2011
- The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivoBlood, 2010
- The DNA-damage response in human biology and diseaseNature, 2009